How many drugs treat skin irritation?

Drug Landscape tracks 10 marketed treatments for skin irritation (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/skin-irritation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

skin irritation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

skin irritation (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating skin irritation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ulesfia	BENZYL ALCOHOL	Shionogi	Pediculicide [EPC]		2009-01-01
Tetracaine Hydrochloride	TETRACAINE	Alcon Labs	Ester Local Anesthetic	Sodium channel protein type 7 subunit alpha	2005-01-01
Galzin	ZINC ACETATE	Eton	zinc acetate		1980-01-01
Domeboro	ALUMINUM ACETATE	Bayer			1976-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Addiclenz	ASPARTAME	Deseret Biologicals, Inc.	Standardized Chemical Allergen [EPC]
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in skin irritation
Bayer · 2 drugs in skin irritation
Deseret Biologicals, Inc. · 1 drug in skin irritation
Eton · 1 drug in skin irritation
Fresenius Kabi · 1 drug in skin irritation
Innocoll · 1 drug in skin irritation
Pfizer · 1 drug in skin irritation
Saint-Joseph University · 1 drug in skin irritation
Shionogi · 1 drug in skin irritation
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in skin irritation
University of Malaya · 1 drug in skin irritation
Alcon Labs · 1 drug in skin irritation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in skin irritation:

Cite this brief

Drug Landscape (2026). skin irritation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/skin-irritation. Accessed 2026-06-10.

skin irritation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing